SCHEMBL1880937

SCHEMBL1880937

Cc1cc(-c2noc(N)c2-c2ccncn2)ccc1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.69
MAPK9 P45984 3/20 0.69
MAPK10 P53779 2/20 0.69
MAPK11 Q15759 2/20 0.69
MAP4K4 O95819 2/20 0.41
CSNK1A1 P48729 2/20 0.41
AURKA O14965 1/20 0.41
DAPK3 O43293 1/20 0.41
JAK2 O60674 1/20 0.41
PRKD3 O94806 1/20 0.41
PAK4 O96013 1/20 0.41
NTRK1 P04629 1/20 0.41
CSF1R P07333 1/20 0.41
RET P07949 1/20 0.41
IGF1R P08069 1/20 0.41
MET P08581 1/20 0.41
PIM1 P11309 1/20 0.41
FGFR1 P11362 1/20 0.41
PRKACA P17612 1/20 0.41
FLT1 P17948 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1875462 0.90 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL1887142 0.89 MAPK14 (0.74) MAPK14MAPK9MAPK10MAPK11MLYCD
SCHEMBL1871452 0.89 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11MLYCD
SCHEMBL1878582 0.86 MAPK14 (0.63) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL1878448 0.85 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL1886432 0.85 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL1877177 0.85 MAPK14 (0.69) MAPK14MAPK9MAPK10MAPK11MLYCD
SCHEMBL4337126 0.85 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL1878304 0.83 MAPK14 (0.59) MAPK14MAPK9MAPK10MAPK11MLYCD
SCHEMBL1878111 0.82 MAPK14 (0.71) MAPK14MAPK9MAPK10MAPK11MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.